What is the growth forecast for the pgd market?

The pgd market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by advancing technology.

What are the key drivers of the pgd market?

Key drivers include increasing infertility rates, genetic disorders, and awareness of pgd benefits, fueling market growth.

What challenges does the pgd market face?

Challenges include high costs, limited awareness, and regulatory restrictions, hindering market expansion.

Which regions lead the pgd market?

North America and Europe are regional leaders, with significant contributions from Asia-Pacific, driving future outlook.

Who are the top companies in the pgd market?

Top companies include Illumina, Thermo Fisher, and CooperSurgical, offering advanced pgd solutions and services.

What future opportunities exist in the pgd market?

Future opportunities include expanding into emerging markets, developing new technologies, and increasing accessibility.

How does technology impact the pgd market?

Advances in technology, such as next-generation sequencing, improve pgd accuracy and efficiency, driving market growth.

What is the regulatory landscape for the pgd market?

The regulatory landscape is complex, with varying laws and guidelines across countries, affecting pgd market size and growth.

What is the future outlook for the pgd market?

The future outlook is positive, with increasing demand for pgd services and advancing technology, driving market expansion.

How Big Is the pre implantation genetic diagnosis pgd Market? Size, Share & Forecast 2033

pre implantation genetic diagnosis pgd by Production Analysis, by Consumption Analysis, by Import Market Analysis (Value & Volume), by Export Market Analysis (Value & Volume), by Price Trend Analysis Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

pre implantation genetic diagnosis pgd Market Overview

The pre implantation genetic diagnosis (PGD) market is a crucial segment of the genetic testing industry, providing valuable insights into the genetic makeup of embryos to identify potential genetic disorders. As the pre implantation genetic diagnosis pgd market size is estimated to be around $140 million, the growth outlook and market forecast indicate a promising future, with the industry expected to expand significantly over the forecast period. The pre implantation genetic diagnosis pgd market is primarily driven by the increasing demand for genetic testing, advancements in technology, and the growing awareness of genetic disorders. The current market size is approximately $140 million, and it is expected to grow at a CAGR of around 10% from 2026 to 2033, driven by macro drivers such as the rising incidence of genetic disorders, technological advancements, and increasing awareness about the importance of genetic testing.

Loading chart…

Key forces shaping the pre implantation genetic diagnosis pgd market include technology shifts towards non-invasive testing methods, regulations supporting the use of genetic testing, and consumer behavior driven by increasing awareness about genetic disorders. The largest region in the pre implantation genetic diagnosis pgd market is North America, while the fastest-growing region is expected to be Asia-Pacific, driven by the growing demand for genetic testing and increasing awareness about genetic disorders. The growth forecast indicates a promising future for the industry, with the market expected to expand significantly over the forecast period, driven by the increasing demand for genetic testing and advancements in technology.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.72 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Light source type, interior design, application, end use, region
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	Roche; Genea Limited; Quest Diagnostics; Illumina, Inc.; Natera, Inc.; Cooper Medical, Inc.; LabCorp; California Pacific Medical Center (CPMC); Thermo Fisher Scientific Inc.; IGENOMIX; Reproductive Genetic Innovations; CombiMatrix
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The pre implantation genetic diagnosis pgd market is witnessing significant growth, driven by various factors. The market dynamics are influenced by a combination of growth drivers, restraints, opportunities, and challenges that shape the industry's trajectory.

Growth Drivers2 items

Advances in genetic testing technologies and increasing awareness about pre implantation genetic diagnosis pgd market size are driving the demand for PGD services, particularly among prospective parents with a history of genetic disorders.

Government initiatives and funding for genetic research, as well as the growing popularity of growth forecast in the PGD market, are expected to fuel the market's expansion in the coming years.

Restraints2 items

High costs associated with PGD procedures and limited insurance coverage are significant restraints in the pre implantation genetic diagnosis pgd market, making it inaccessible to a large portion of the population.

Stringent regulatory frameworks and ethical concerns surrounding PGD, such as the potential for sex selection and genetic modification, may hinder the market's growth and impact the pre implantation genetic diagnosis pgd market size.

Opportunities2 items

Increasing demand for non-invasive prenatal testing and the growing trend of pre implantation genetic diagnosis pgd market services are creating new opportunities for companies to develop innovative products and services.

Expansion into emerging markets, particularly in Asia-Pacific and Latin America, presents a significant opportunity for growth forecast in the PGD market, driven by rising awareness and improving healthcare infrastructure.

Challenges2 items

The pre implantation genetic diagnosis pgd market faces challenges related to standardization and quality control, as well as the need for skilled professionals to perform complex genetic testing procedures.

Competition from alternative reproductive technologies, such as preimplantation genetic screening, may impact the pre implantation genetic diagnosis pgd market size and require companies to adapt their strategies to remain competitive.

Market Segmentation

Loading chart…

The pre implantation genetic diagnosis pgd market can be segmented based on application, which is a crucial aspect of pre implantation genetic diagnosis pgd segmentation. This market is divided into several subtypes, including aneuploidy screening, single gene disorder, and structural chromosomal rearrangement. Each of these subtypes contributes significantly to the overall market size, with aneuploidy screening being the largest segment due to its widespread application in identifying genetic disorders.

Aneuploidy screening accounts for the largest share of the market, driven by the increasing incidence of genetic disorders and the rising demand for preimplantation genetic testing. Single gene disorder is another significant segment, as it enables the identification of specific genetic mutations that can cause inherited diseases. Structural chromosomal rearrangement is also an essential segment, as it helps in detecting chromosomal abnormalities that can lead to birth defects or infertility.

The market taxonomy of pre implantation genetic diagnosis pgd is complex, with each segment having its own set of applications and end-users. Understanding these segments is crucial for industry players to develop targeted strategies and capitalize on the growing demand for preimplantation genetic diagnosis services. By analyzing the market segmentation, companies can identify areas of opportunity and develop innovative solutions to address the evolving needs of the market.

Regional Insights

Loading chart…

The pre implantation genetic diagnosis pgd market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of PGD services, favorable policies, and significant investments in healthcare infrastructure. Key drivers for North America include high ecosystem maturity, increasing awareness about genetic disorders, and a well-established infrastructure for PGD services.

In Europe, key drivers include a high demand for PGD services, stringent regulations ensuring quality services, and a significant investment in research and development. Asia Pacific's growth is further fueled by a large demographic population, rising awareness about genetic diseases, and a growing middle-class population with increasing disposable income. Latin America and Middle East & Africa are expected to experience moderate growth, driven by improving infrastructure, increasing adoption of PGD services, and favorable government policies.

The regional forecast indicates that the pre implantation genetic diagnosis pgd market will continue to grow, driven by increasing demand for genetic testing and counseling services. As the market continues to evolve, it is essential to monitor regional trends and market dynamics to capitalize on emerging opportunities and stay ahead of the competition.

Competitive Landscape

The pre implantation genetic diagnosis pgd market exhibits a moderately consolidated structure, with a mix of global players and local companies competing on various levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. The pre implantation genetic diagnosis pgd competitive landscape is characterized by high competition, with key players focusing on differentiation through technology, service model, and channel strength. Global players are expanding their presence through strategic partnerships and acquisitions, while local companies are focusing on regional expansion and customization.

Companies in the pre implantation genetic diagnosis pgd market are adopting various strategies to stay competitive, including M&A, partnerships, product launches, expansion, R&D, and localization. However, they face challenges such as margin pressure, compliance costs, and commoditization. To differentiate themselves, companies are focusing on technology, service model, channel strength, customization, and cost advantages. The following companies are pursuing specific strategic focuses:

Roche: regional expansion

Genea Limited: premium pricing

Illumina, Inc.: innovation pipeline

Natera, Inc.: OEM tie-ups

Thermo Fisher Scientific Inc.: local manufacturing

Quest Diagnostics: vertical integration

Key pre implantation genetic diagnosis pgd Companies12 items

Roche

Genea Limited

Quest Diagnostics

Illumina, Inc.

Natera, Inc.

Cooper Medical, Inc.

LabCorp

California Pacific Medical Center (CPMC)

Thermo Fisher Scientific Inc.

IGENOMIX

Reproductive Genetic Innovations

CombiMatrix

Market Ecosystem

The pre implantation genetic diagnosis pgd ecosystem encompasses a complex network of participants, spanning from technology providers to end users. It can be broadly segmented into upstream, midstream, and downstream components, with value created and captured at each stage. Upstream participants provide raw materials and components, while midstream entities integrate these inputs into finished products. Downstream channels and end users ultimately receive and utilize these products, driving demand and influencing the ecosystem's evolution.

Technology providers — supply genetic testing platforms

Raw material/component suppliers — provide reagents and equipment

OEMs / manufacturers — produce pgd devices and software

System integrators / EPCs — configure and install pgd systems

Distributors / channel partners — deliver pgd products to clinics

Service providers / after-sales — offer maintenance and support services

End users / buyers — fertility clinics and medical institutions

In the pre implantation genetic diagnosis pgd ecosystem, control points are primarily held by technology providers and regulatory bodies, as they influence adoption through standards and approvals. Dependency risks arise from input constraints, such as limited availability of certain reagents, and switching costs are high due to the specialized nature of pgd equipment. Partnerships between technology providers and distributors can facilitate the flow of value, while interoperability requirements may vary by region, affecting the ecosystem's dynamics in different areas.

Recent Industry Insights

The pre implantation genetic diagnosis pgd industry trends have witnessed significant developments over the last 12-18 months. Notable partnerships, such as the collaboration between genetic testing companies and fertility clinics, have expanded the reach of PGD services. Furthermore, there have been strategic mergers and acquisitions, including the acquisition of smaller genetic testing firms by larger companies, which has led to increased consolidation in the market.

Recent product launches, such as advanced next-generation sequencing technologies, have improved the accuracy and efficiency of PGD testing. Additionally, regulatory changes, including updates to guidelines for PGD testing, have been implemented to ensure the safe and effective use of these technologies. These developments have contributed to a shift in pre implantation genetic diagnosis pgd industry trends, with an increased focus on innovative technologies and expanded access to PGD services.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the pre implantation genetic diagnosis pgd market. The market attractiveness is driven by increasing demand for genetic testing and advancements in technology. The competitive intensity is moderate, with key players focusing on innovation and expansion. The pre implantation genetic diagnosis pgd market outlook indicates a positive long-term outlook, with growth opportunities in emerging markets.

The innovation landscape is evolving, with new technologies and products being introduced. However, the demand–supply balance is a key concern, with supply chain disruptions and regulatory challenges affecting the market. Key risk factors include regulatory changes and technological advancements. Overall, the pre implantation genetic diagnosis pgd market is expected to grow, driven by increasing awareness and adoption of genetic testing.

11 items

1. Executive Summary

2. pre implantation genetic diagnosis pgd Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global pre implantation genetic diagnosis pgd Market Outlook & Forecast (2021-2033) Value (USD Million)

7. Global pre implantation genetic diagnosis pgd Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global pre implantation genetic diagnosis pgd Market by: Regions (Value)

8. Global pre implantation genetic diagnosis pgd Market Competition by Key Manufacturers

8.1. Global pre implantation genetic diagnosis pgd Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global pre implantation genetic diagnosis pgd: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Roche

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Genea Limited

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Quest Diagnostics

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Illumina, Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Natera, Inc.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Cooper Medical, Inc.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. LabCorp

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. California Pacific Medical Center (CPMC)

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Thermo Fisher Scientific Inc.

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. IGENOMIX

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Reproductive Genetic Innovations

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. CombiMatrix

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

16 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global pre implantation genetic diagnosis pgd Market

Figure 4: Global pre implantation genetic diagnosis pgd Market: Drivers

Figure 5: Global pre implantation genetic diagnosis pgd Market: Challenges

Figure 6: Global pre implantation genetic diagnosis pgd Market: Trends

Figure 7: Global pre implantation genetic diagnosis pgd Market: Opportunity

Figure 8: Global pre implantation genetic diagnosis pgd Market: Restraint

Figure 9: Global pre implantation genetic diagnosis pgd Market: Porter's Five Forces

Figure 10: Global pre implantation genetic diagnosis pgd Market Value (USD Million) By Region

Figure 11: Global pre implantation genetic diagnosis pgd Market Share (%) By: Regions (2024)

Figure 12: Top 5 Manufacturers

Figure 13: Top 3 Manufacturers

Figure 14: Global pre implantation genetic diagnosis pgd Market Value (USD Million) By Region

Figure 15: Global pre implantation genetic diagnosis pgd Market Share (%) By: Regions (2032)

Figure 16: Data Triangulation

List of Tables

47 items

Table 1: Market Segmentation Analysis

Table 2: Global pre implantation genetic diagnosis pgd Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 3: Global pre implantation genetic diagnosis pgd Market Value (USD Million) By Region

Table 4: Global pre implantation genetic diagnosis pgd Market Share (%) By Region

Table 5: North America Market Value (USD Million) (2020-2024) By Country

Table 6: Europe Market Value (USD Million) (2020-2024) By Country

Table 7: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 8: South America Market Value (USD Million) (2020-2024) By Country

Table 9: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 10: Global pre implantation genetic diagnosis pgd Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 11: Global pre implantation genetic diagnosis pgd Market: Profiled Players Head Office And Area Served

Table 12: Key Players Global pre implantation genetic diagnosis pgd Market:

Table 13: Mergers & Acquisitions, Expansion Plans

Table 14: Roche Basic Information And Sales Area

Table 15: Roche. Products Portfolio

Table 16: Genea Limited Basic Information And Sales Area

Table 17: Genea Limited. Products Portfolio

Table 18: Quest Diagnostics Basic Information And Sales Area

Table 19: Quest Diagnostics. Products Portfolio

Table 20: Illumina, Inc. Basic Information And Sales Area

Table 21: Illumina, Inc.. Products Portfolio

Table 22: Natera, Inc. Basic Information And Sales Area

Table 23: Natera, Inc.. Products Portfolio

Table 24: Cooper Medical, Inc. Basic Information And Sales Area

Table 25: Cooper Medical, Inc.. Products Portfolio

Table 26: LabCorp Basic Information And Sales Area

Table 27: LabCorp. Products Portfolio

Table 28: California Pacific Medical Center (CPMC) Basic Information And Sales Area

Table 29: California Pacific Medical Center (CPMC). Products Portfolio

Table 30: Thermo Fisher Scientific Inc. Basic Information And Sales Area

Table 31: Thermo Fisher Scientific Inc.. Products Portfolio

Table 32: IGENOMIX Basic Information And Sales Area

Table 33: IGENOMIX. Products Portfolio

Table 34: Reproductive Genetic Innovations Basic Information And Sales Area

Table 35: Reproductive Genetic Innovations. Products Portfolio

Table 36: CombiMatrix Basic Information And Sales Area

Table 37: CombiMatrix. Products Portfolio

Table 38: Global pre implantation genetic diagnosis pgd Market Value (USD Million) By Region

Table 39: Global pre implantation genetic diagnosis pgd Market Share (%) By Region (2025-2032)

Table 40: North America Market Value (USD Million) (2025-2032) By Country

Table 41: Europe Market Value (USD Million) (2025-2032) By Country

Table 42: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 43: South America Market Value (USD Million) (2025-2032) By Country

Table 44: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 45: Research Programs/Design For This Report

Table 46: Key Data Information From Secondary Sources

Table 47: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

pre implantation genetic diagnosis pgd Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.72 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Light source type, interior design, application, end use, region
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	Roche; Genea Limited; Quest Diagnostics; Illumina, Inc.; Natera, Inc.; Cooper Medical, Inc.; LabCorp; California Pacific Medical Center (CPMC); Thermo Fisher Scientific Inc.; IGENOMIX; Reproductive Genetic Innovations; CombiMatrix
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Government initiatives and funding for genetic research, as well as the growing popularity of growth forecast in the PGD market, are expected to fuel the market's expansion in the coming years.

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Regional Insights

Loading chart…

Competitive Landscape

Roche: regional expansion

Genea Limited: premium pricing

Illumina, Inc.: innovation pipeline

Natera, Inc.: OEM tie-ups

Thermo Fisher Scientific Inc.: local manufacturing

Quest Diagnostics: vertical integration

Key pre implantation genetic diagnosis pgd Companies12 items

Roche

Genea Limited

Quest Diagnostics

Illumina, Inc.

Natera, Inc.

Cooper Medical, Inc.

LabCorp

California Pacific Medical Center (CPMC)

Thermo Fisher Scientific Inc.

IGENOMIX

Reproductive Genetic Innovations

CombiMatrix

Market Ecosystem

Technology providers — supply genetic testing platforms

Raw material/component suppliers — provide reagents and equipment

OEMs / manufacturers — produce pgd devices and software

System integrators / EPCs — configure and install pgd systems

Distributors / channel partners — deliver pgd products to clinics

Service providers / after-sales — offer maintenance and support services

End users / buyers — fertility clinics and medical institutions

Recent Industry Insights

Analyst Overview

Table of Contents